The EIF4A2 Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population in which the EIF4A2 gene has been disrupted within the human A-549 lung adenocarcinoma cell line. This polyclonal preparation offers a heterogeneous pool of edited cells derived from the parental line, enabling loss-of-function analysis without the need for single-cell clone isolation. The model is specifically designed for studying EIF4A2-dependent translational control in a cancer setting.
A-549 cells are an adherent epithelial line originally isolated from the lung tissue of a 58-year-old male with adenocarcinoma. They are widely used as a model for non-small cell lung cancer, retaining characteristics of alveolar basal epithelial cells and serving as a platform for investigating alveolar barrier function, surfactant metabolism, and oncogenic signaling. Their well-documented sensitivity to growth factors and chemotherapeutic agents makes them a relevant host for probing translation regulatory networks.
EIF4A2 encodes a DEAD-box RNA helicase that utilizes ATP hydrolysis to unwind secondary structures within the 5′ untranslated regions (UTRs) of mRNA. As a core component of the eIF4F complex, it directly associates with the cap-binding protein eIF4E and the scaffold protein eIF4G, while its activity is positively modulated by eIF4B and eIF4H and negatively regulated by the tumor suppressor PDCD4. Signaling through growth factor receptors, such as EGFR, activates the PI3K/AKT/mTORC1 axis; mTORC1 phosphorylates 4E-BP1, leading to its dissociation from eIF4E and subsequent assembly of the eIF4F complex. Additionally, the transcription factor MYC promotes expression of eIF4F components. Through this network, EIF4A2 facilitates the translation of a subset of mRNAs bearing highly structured 5′ UTRs, including those encoding MYC, CCND1, and BCL2, which are critical for cell cycle progression and apoptosis resistance.
Disruption of EIF4A2 in A-549 cells is expected to specifically reduce the translation efficiency of mRNAs with complex 5′ leaders, thereby attenuating the expression of pro-proliferative and pro-survival factors. This model provides a powerful tool to explore the dependency of lung adenocarcinoma cells on cap-dependent translation for growth and viability, and to interrogate the translational output downstream of mTORC1. It is also suited for studying mechanisms of resistance to mTOR inhibitors and for evaluating the effects of eIF4A-targeting compounds, such as rocaglamide, in a disease-relevant context.
Key applications include polysome profiling to assess global translation changes, RNA-seq of polysome-associated mRNA for translatome analysis, and quantitative assays such as Western blotting and RT-qPCR to verify target gene expression. Functional studies, including cell viability, proliferation, and drug sensitivity assays with eIF4A inhibitors, are facilitated by this knockout model. Moreover, the cells can be used for co-immunoprecipitation experiments to delineate eIF4F complex assembly in the absence of EIF4A2. For detailed technical inquiries, please contact Ascent Research.
